HCACR dividend yield: 4.00%. PFE dividend yield: 6.77%. HCACR is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in HCACR shares. Pfizer offers one of the highest dividend yields among blue-chip pharma companies. Post-COVID revenue normalization has pressured earnings, but the dividend has been maintained. Pfizer's acquisition of Seagen adds oncology depth. With 14+ consecutive years of no dividend cuts, income investors see the high yield as an opportunity.
HCACR is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in HCACR shares.
Pfizer offers one of the highest dividend yields among blue-chip pharma companies. Post-COVID revenue normalization has pressured earnings, but the dividend has been maintained. Pfizer's acquisition of Seagen adds oncology depth. With 14+ consecutive years of no dividend cuts, income investors see the high yield as an opportunity.
Is HCACR or PFE better for dividend income in 2026?
HCACR currently offers a 4.00% yield (2.00/share/year) while PFE offers 6.77% (1.68/share/year). PFE provides higher current income. However, HCACR has grown its dividend faster (5% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in HCACR vs PFE earn per year?
With $10,000 invested today: HCACR pays approximately $400/year. PFE pays approximately $677/year. With DRIP reinvestment over 10 years, these grow to $899/year (HCACR) and $5,820/year (PFE).
Does HCACR or PFE pay monthly dividends?
HCACR pays quarterly dividends. PFE pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this HCACR vs PFE comparison by email
Save your analysis + get weekly dividend insights. Free forever.